Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1/2 6Phase 1 6Phase 3 4Phase NA 2Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 15Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Carcinoid Tumor 2Serotonin Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Disease 1Digestive System Neuroendocrine Tumor G1 1Colorectal Neoplasms 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenoma 1Acromegaly 1

Interventions

arginyllysine 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Carcinoid Tumor × NET × Clear all
NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Advanced Accelerator Applications

Phase 4 Completed
42 enrolled 11 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡